Bicara Therapeutics Inc. Common Stock Net Assets
Bicara Therapeutics Inc. Common Stock net assets. Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) has net assets worth $468.77 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($512.24 Million) and total liabilities ($43.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore BCAX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $468.77 Million |
| % of Total Assets | 91.51% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 71.74 |
Net Assets of Bicara Therapeutics Inc. Common Stock (2022–2025)
Net assets of Bicara Therapeutics Inc. Common Stock from 2022 to 2025. This chart illustrates how Bicara Therapeutics Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Bicara Therapeutics Inc. Common Stock to measure how much of total assets are equity-financed.
Annual Net Assets for Bicara Therapeutics Inc. Common Stock (2022–2025)
The table below shows the annual net assets of Bicara Therapeutics Inc. Common Stock from 2022 to 2025. For live market cap and overall valuation, see Bicara Therapeutics Inc. Common Stock (BCAX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $401.45 Million | -18.38% |
| 2024-12-31 | $491.88 Million | +125.11% |
| 2023-12-31 | $218.51 Million | +1364.66% |
| 2022-12-31 | $-17.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bicara Therapeutics Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25793000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Bicara Therapeutics Inc. Common Stock Net Assets Breakdown (December 2025)
Bicara Therapeutics Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $243.00K | 0.06% |
| Other Components | $760.17 Million | 189.35% |
| Total Equity | $401.45 Million | 100.00% |
Bicara Therapeutics Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Bicara Therapeutics Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sturm Ruger & Company Inc
NYSE:RGR
|
$592.95 Million |
|
Beijing Telesound Electronics Co Ltd
SHE:003004
|
$592.96 Million |
|
Wheels India Limited
NSE:WHEELS
|
$592.99 Million |
|
BRASKEM PFD ADR/2 O.N.
F:BRD
|
$593.02 Million |
|
Anhui Province Natural Gas Development Co Ltd
SHG:603689
|
$592.70 Million |
|
Liaoning Hongyang Energy Resource Invest Co Ltd
SHG:600758
|
$591.97 Million |
|
Vaalco Energy Inc
NYSE:EGY
|
$591.78 Million |
|
Nilfisk Holding A/S
CO:NLFSK
|
$591.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bicara Therapeutics Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 491,875,000 to 401,452,000, a change of -90,423,000 (-18.4%).
- Net loss of 137,950,000 reduced equity.
- New share issuances of 29,498,000 increased equity.
- Other comprehensive income increased equity by 243,000.
- Other factors increased equity by 17,786,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-137.95 Million | -34.36% |
| Share Issuances | $29.50 Million | +7.35% |
| Other Comprehensive Income | $243.00K | +0.06% |
| Other Changes | $17.79 Million | +4.43% |
| Total Change | $- | -18.38% |
Book Value vs Market Value Analysis
This analysis compares Bicara Therapeutics Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-0.33 | $8.96 | x |
| 2023-12-31 | $4.22 | $8.96 | x |
| 2024-12-31 | $9.04 | $8.96 | x |
| 2025-12-31 | $7.34 | $8.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bicara Therapeutics Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-34.36%) is below the historical average (-17.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-36.12 Million |
| 2023 | -23.79% | 0.00% | 0.00x | 1.07x | $-73.84 Million |
| 2024 | -13.82% | 0.00% | 0.00x | 1.16x | $-117.18 Million |
| 2025 | -34.36% | 0.00% | 0.00x | 1.07x | $-178.10 Million |
Industry Comparison
This section compares Bicara Therapeutics Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $468.77 Million | 0.00% | 0.09x | $592.91 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was … Read more